证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-173 江苏恒瑞医药股份有限公司 关于 2025 年 A 股员工持股计划非交易过户完成的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司 2025 年 A 股员工持股计划》的相关规定，本次员工持股计划的 存续期为 60 个月，自公司股东会审议通过本员工持股计划且公司公告相应批次 标的股票过户至本员工持股计划名下之日起计算。本次员工持股计划所获标的股 票分三期解锁，解锁时点分别为自公司公告相应批次标的股票过户至本次员工持 股计划名下之日起满 12 个月、24 个月、36 个月，每期解锁的标的股票比例分别 为 40%、30%、30%，各年度实际解锁比例和数量根据公司业绩考核和个人考核结 果计算确定。本次员工持股计划所取得的标的股票，因上市公司分配股票股利、 资本公积转增等情形所衍生取得的股份，亦应遵守上述股份锁定安排。 公司将持续关注 2025 年 A 股员工持股计划的实施进展情况，并按照相关法 律法规的规定及时履行信息披露义务。敬请广大投资者注 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-176 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 HRS-2430 注射液为静脉全身麻醉药，已上市的同类产品有依托咪酯、咪达 唑仑、瑞马唑仑等。经查询，2024 年依托咪酯、咪达唑仑、瑞马唑仑全球销售 额合计约为 7.73 亿美元。截至目前，HRS-2430 注射液相关项目累计研发投入约 2,460 万元。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发关于 HRS-2430 注射液的《药物临 床试验批准通知书》，将于近期开展临床试验。现将相关情况公告如下： 一、药物的基本情况 药物名称：HRS-2430 注射液 剂 型：注射剂 申请事项：临床试验 受 理 号：CXHL2500810、CXHL2500811 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 4 日受理的 HRS-2430 注射液临 ...

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-174 江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划第一次持有人会议决议 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、持有人会议召开情况 江苏恒瑞医药股份有限公司（以下简称"公司"）2025 年 A 股员工持股计 划第一次持有人会议于 2025 年 11 月 7 日以通讯会议的方式召开。会议由公司董 事会秘书刘笑含主持。本次会议应出席持有人 1,274 人，实际出席持有人 1,274 人，代表 2025 年 A 股员工持股计划有表决权的份额为 13,511,100 份，占 2025 年 A 股员工持股计划有表决权份额总数的 100%。 本次会议的召集、召开和表决程序符合相关法律法规、规范性文件及公司 2025 年 A 股员工持股计划的有关规定，会议合法有效。 二、持有人会议审议情况 经与会持有人逐项审议，通过以下议案： 根据《江苏恒瑞医药股份有限公司 2025 年 A 股员工持股计划》和《江苏恒 瑞医药股份有限公司 2025 年 A ...

一、药物的基本情况 药物名称：SHR-4610 注射液 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司上海盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准签发关于 SHR-4610 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。现 将相关情况公告如下： 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-175 三、风险提示 剂 型：注射剂 根据我国药品注册相关的法律法规要求，药物在获得药物临床试验批准通知 书后，尚需开展临床试验并经国家药监局审评、审批通过后方可生产上市。药品 从研制、临床试验报批到投产的周期长、环节多，药品研发及至上市容易受到一 申请事项：临床试验 些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投资风险。公司将 按国家有关规定积极推进上述研发项目，并及时对项目后续进展情况履行信息披 露义务。 受 理 号：CXSL2500686 特 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of HRS-2430 injection, a new intravenous general anesthetic [1] Group 1: Product Development - HRS-2430 injection is designed for intravenous general anesthesia, competing with existing products such as etomidate, midazolam, and remimazolam [1] - The total global sales of etomidate, midazolam, and remimazolam are approximately $773 million in 2024 [1] - The cumulative R&D investment for the HRS-2430 injection project has reached approximately 24.6 million yuan [1]

Core Viewpoint - The Medical Health R Index (480016) closed at 7535.01 points, down 0.39%, with a trading volume of 21.869 billion yuan and a turnover rate of 0.89% on November 7 [1] Group 1: Index Performance - The index had 26 stocks rising, with Xinhecheng leading at a 4.9% increase, while 23 stocks fell, with Zaiqing Pharmaceutical leading the decline at 4.35% [1] - The top ten constituent stocks of the Medical Health R Index are primarily in the pharmaceutical and medical sectors, with notable weights and market capitalizations [1] Group 2: Key Constituents - WuXi AppTec (sh603259) holds a weight of 13.66% with a market cap of 282.98 billion yuan, closing at 94.84 yuan, down 0.89% [1] - Hengrui Medicine (sh600276) has an 11.00% weight, a market cap of 408.72 billion yuan, and closed at 61.58 yuan, down 1.35% [1] - Mindray Medical (sz300760) has a weight of 7.57%, a market cap of 249.51 billion yuan, and closed at 205.79 yuan, down 0.27% [1] - Other notable constituents include United Imaging Healthcare (sh688271), Pianzai Shou (sh600436), and Xinhecheng (sz002001), which saw a 4.9% increase [1] Group 3: Capital Flow - The Medical Health R Index constituents experienced a net outflow of 240 million yuan from institutional investors and 119 million yuan from retail investors, while retail investors saw a net inflow of 359 million yuan [1] - Specific stocks like Huazhong Pharmaceutical (000999) and Yuyue Medical (002223) showed significant net inflows and outflows among different investor types [2]

Core Viewpoint - Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4610 injection, an innovative anti-tumor drug developed by the company [1] Group 1: Company Developments - The subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration for SHR-4610 injection [1] - SHR-4610 injection is intended for use in clinical trials for late-stage solid tumors [1] - The total research and development investment for the related project has reached approximately 7.36 million yuan [1] Group 2: Regulatory and Market Context - Following the approval notice, the drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be manufactured and marketed [1]

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative anti-tumor drug SHR-4610 injection, which shows promising anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors [1] Company Summary - The company’s subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., is responsible for the clinical trial of SHR-4610 injection [1] - The total research and development investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1] Industry Summary - The approval of SHR-4610 injection for clinical trials indicates a positive development in the field of innovative anti-tumor therapies, potentially enhancing the company's position in the pharmaceutical industry [1]

Core Viewpoint - Heng Rui Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-2430 injection, a new intravenous general anesthetic [1] Company Summary - HRS-2430 injection is positioned as a competitor to existing products such as etomidate, midazolam, and remimazolam [1] - The total global sales of etomidate, midazolam, and remimazolam are approximately $773 million for the year 2024 [1] - The cumulative R&D investment for the HRS-2430 injection project has reached approximately 24.6 million yuan [1]

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Summary by Categories - **Clinical Trial Approval** - The National Medical Products Administration has issued a clinical trial approval notice for SHR-4610 injection [1] - The clinical trials are set to commence in the near future [1] - **Product Development** - SHR-4610 injection is an innovative anti-tumor drug independently developed by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - **Research and Development Investment** - The cumulative R&D investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1]